Page 155 - Read Online
P. 155

Nevola et al. Hepatoma Res 2018;4:55  I  http://dx.doi.org/10.20517/2394-5079.2018.38                                           Page 19 of 22


                   Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ. Toward a more complete understanding of the association between a
                   hepatitis C sustained viralresponse and cause-specific outcomes. Hepatology 2015;62:355-64.
               111.  Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim
                   F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S,
                   Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis
                   C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS
                   CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.
                   Gastroenterology 2017;152:142-156.e2.
               112.  Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int
                   2018;38 Suppl 1:139-45.
               113.  Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting
                   antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
               114.  Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J
                   Hepatol 2017; pii: S0168-8278(17)32273-0.
               115.  Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-
                   acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
               116.  Ramadori P, Cubero FJ, Liedtke C, Trautwein C, Nevzorova YA. Alcohol and hepatocellular carcinoma: adding fuel to the flame. Cancers
                   (Basel) 2017;9. pii: E130.
               117.  Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010;16:3603-15.
               118.  Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M.
                   Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol
                   Hepatol;11:95-101.
               119.  Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and non-
                   alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS One 2017;12:e0186715.
               120.  Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol
                   and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-
                   31.
               121.  Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, Graubard BI, Freedman ND, McGlynn KA. Alcohol consumption, folate
                   intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev 2013;22:415-21.
               122.  Matsuhashi T, Yamada N, Shinzawa H, Takahashi T. Effect of alcohol on tumor growth of hepatocellular carcinoma with type C cirrhosis.
                   Intern Med 1996;35:443-8.
               123.  Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F,
                   Chedid A, Bedossa P; PANFIBROSIS Group. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-65.
               124.  Heckley GA, Jarl J, Asamoah BO, G-Gerdtham U. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis
                   of the current literature. BMC Cancer 2011;11:446.
               125.  Joshi K, Kohli A, Manch R, Gish R. Alcoholic liver disease: high risk or low risk for developing hepatocellular carcinoma? Clin Liver Dis
                   2016;20:563-80.
               126.  Galati G, Dell’Unto C, Vespasiani-Gentilucci U, Vincentis A, Gallo P, Guidi A, Picardi A. Hepatocellular carcinoma in alcoholic liver
                   disease: current management and recent advances. Rev Recent Clin Trials 2016;11:238-52.
               127.  Salameh H, Raff E, Erwin A, Seth D, Nischalke HD, Falleti E, Burza MA, Leathert J, Romeo S, Molinaro A, Corradini SG, Toniutto
                   P, Spengler U, Daly A, Day CP, Kuo YF, Singal AK. PNPLA3 gene polymorphism is associated with predisposition to and severity of
                   alcoholic liver disease. Am J Gastroenterol 2015 Jun;110:846-56.
               128.  Nahon P, Nault JC. Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. Liver Int 2017;37:1591-1601.
               129.  Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci
                   2013;92:3-9.
               130.  Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ. Synergism between obesity and alcohol in increasing the risk of
                   hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 2013;177:333-42.
               131.  Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis 2012;16:839-50.
               132.  Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma:
                   synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13.
               133.  Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami
                   S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan.
                   Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-
                   33.
               134.  N’Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M. Risk factors for
                   hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062-8.
               135.  Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Kawamura Y, Yatsuji H, Suzuki F, Suzuki Y, Arase Y, Kumada H. Diabetes
                   mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: a preliminary report. Hepatol Res 2007;37:517-23.
               136.  Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in
                   blacks and whites in the U.S. Cancer 2004;101:1009-17.
               137.  Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS. Heavy
                   alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 2013;58:730-5.
               138.  Chung NS, Kwon OS, Park CH, Kim YN, Cho GH, Lee JJ, Kim GH, Kim HO, Ko KI, Yu SK, Kwon KA, Kim YS, Choi DJ, Kim JH.
   150   151   152   153   154   155   156   157   158   159   160